ABCC8: IHC Expression in Cancer and Radioligand Target Profile
ABCC8, ATP binding cassette subfamily C member 8, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, ABCC8 staining is highest in testicular cancer (100% of samples positive), ovarian cancer (100% of samples positive) and bladder cancer (100% of samples positive). Clinical status: FDA-approved drug (any modality).
Is ABCC8 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze ABCC8 freeIs ABCC8 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in testicular cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
ABCC8 IHC staining by cancer type
Protein expression of ABCC8 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Testicular Cancer | 0.97 | High | 100% |
| Ovarian Cancer | 0.67 | High | 100% |
| Bladder Cancer | 0.67 | High | 100% |
| Cervical Cancer | 0.63 | High | 100% |
| Prostate Cancer | 0.63 | High | 100% |
| Gastric Cancer | 0.63 | High | 89% |
| Endometrial Cancer | 0.59 | High | 89% |
| Neuroendocrine Tumors | 0.56 | High | 100% |
| Breast Cancer | 0.55 | High | 100% |
| Liver Cancer | 0.55 | High | 73% |
| Skin Cancer | 0.53 | High | 100% |
| Colorectal Cancer | 0.50 | Medium | 90% |
| Pancreatic Cancer | 0.47 | Medium | 83% |
| Melanoma | 0.47 | Medium | 80% |
| Head and Neck Cancer | 0.33 | Medium | 75% |
| Glioma | 0.30 | Medium | 70% |
| Lung Cancer | 0.27 | Medium | 50% |
| Thyroid Cancer | 0.25 | Medium | 75% |
| Lymphoma | 0.21 | Medium | 46% |
| Kidney Cancer | 0.06 | Low | 18% |
Is ABCC8 internalized?
Nuclens has not yet extracted internalization evidence for ABCC8. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.
ABCC8 clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for ABCC8 yet. Search ClinicalTrials.gov for ABCC8 trials.
ABCC8 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See ABCC8 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
ABCC8 gene essentiality (DepMap)
CRISPR knockout effect across 1239 cancer cell lines: 0.05 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related testicular cancer radioligand targets
HER3 (ERBB3) · c-MET (MET) · STEAP2 · KIT · SSTR2 · HER2 (ERBB2) · TMEFF2 · Mesothelin (MSLN)
See all radioligand therapy targets in testicular cancer.
See how ABCC8 ranks against 15,000 targets for your indication.
Analyze ABCC8 freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.